Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.51
-0.0300-1.95%
Volume:3.08M
Turnover:4.71M
Market Cap:520.95M
PE:-2.32
High:1.57
Open:1.57
Low:1.51
Close:1.54
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.73
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.19
PE(LYR):-1.75

Loading ...

U.S. RESEARCH ROUNDUP-CME Group, M&T Bank, PNC Financial Services

Reuters
·
Apr 16

NASD Most Active Issues

Dow Jones
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Unusually active option classes on open April 15th

TIPRANKS
·
Apr 15

Allogene enrolls Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases

Reuters
·
Apr 15

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

GlobeNewswire
·
Apr 15

BRIEF-Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock

Reuters
·
Apr 15

Allogene prices 87,500,000-share follow-on offering at $2 per share

Reuters
·
Apr 15

Allogene Therapeutics Inc - Prices Public Offering of 87,500,000 Shares at $2.00 per Share

THOMSON REUTERS
·
Apr 15

Top Midday Decliners

MT Newswires Live
·
Apr 15

Canaccord Genuity Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
Apr 14

Bernstein Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
Apr 14

Allogene Therapeutics Shares Down 5.2% Premarket After Co Announces $175 Mln Stock Offering Plans

THOMSON REUTERS
·
Apr 14

NASD Most Active Issues

Dow Jones
·
Apr 14

Allogene Therapeutics Announces Proposed Public Offering Of $175 Million Of Common Stock

Reuters
·
Apr 14

BUZZ-Allogene slips on $175 mln stock offering plans after blood cancer study

Reuters
·
Apr 14

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments

TIPRANKS
·
Apr 14

Allogene Therapeutics Inc - Offering $175 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
Apr 14

Allogene Therapeutics plans $175 million common stock offering

Reuters
·
Apr 14

Allogene Therapeutics Inc - Net Proceeds Expected to Be Used for General Corporate Purposes Including Clinical Trials and R&D

THOMSON REUTERS
·
Apr 14